Forget the Cash ISA. Here are 2 FTSE 100 stocks I’d buy and hold forever

These FTSE 100 (INDEXFTSE: UKX) income champions yield nearly three times as much as the best Cash ISA on the market today says Rupert Hargreaves.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

With the best Cash ISA on the market today offering an interest rate of just 1.5%, I think it’s best to overlook this meagre level of income and invest your money in shares instead.

Indeed, the FTSE 100 is full of blue-chip income stocks that offer both a higher rate of income and the potential for capital gains as well. Today I’m going to highlight just two of these FTSE 100 income and growth champions.

Buy-and-hold

AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) both offer a highly attractive combination of income and growth. At the same time, these two pharmaceutical businesses are extremely defensive. The global healthcare market is only growing, and it isn’t subject to cyclical factors like so many other industries, so I think I am quite safe in saying that these companies will still be around 50 years from now doing what they do best, developing, producing and selling treatments for patients all over the world.

Should you invest £1,000 in Polymetal right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Polymetal made the list?

See the 6 stocks

Both Astra and Glaxo are experts in their respective fields. Over the past few years, Glaxo has been building out its consumer healthcare products business, which produces and supplies products such as Sensodyne toothpaste and Panadol. In December 2018, the company announced an agreement with US drugs giant Pfizer to form a world-leading consumer healthcare joint venture, which the partners aim to spin off within three years.

This transaction could potentially unlock billions of dollars in value for Glaxo’s shareholders as analysts have said many times in the past that they believe the component parts of Glaxo are worth more apart than they are together.

The company also owns a share in ViiV Healthcare, a world leader in the development and production of HIV medication and Glaxo is a world leader in the production of vaccines.

Astra, meanwhile, has carved out a niche for itself in the oncology market. Management has been focusing its efforts on this fast-growing market for the past few years, and now the company is bringing a number of new treatments to market which could end up becoming multibillion-dollar anti-cancer drugs. For the first quarter of 2019 overall product sales leapt 14% at constant exchange rates, led by a 59% increase in sales at the group’s oncology business. 

The future is exciting

The future for both of these companies is exciting and I think shareholders will be well rewarded over the next five to 10 years as Astra’s oncology pipeline starts to yield results and Glaxo spins off its consumer healthcare business.

In the meantime, shareholders can pick up a market-beating dividend yield from both. At the time of writing, shares in Glaxo support a dividend yield of 5.1% and shares in Astra yield 3.6%. Shares in both businesses are not particularly expensive either. Glaxo trades at a forward P/E of just 14, compared to the UK pharmaceutical industry average of 18.6, and Astra is dealing at a 2020 P/E of 17.9.

So overall, if you are looking to break free from the world of the low returns in the Cash ISA market, then I think it is worth checking out Astra and Glaxo for their defensive qualities, attractive valuations and market-beating dividend yields.

Should you buy Polymetal now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

The dividend yield on this FTSE 100 stock has jumped 50% in a year. Time to buy?

Jon Smith explains why the yield on a FTSE 100 share has risen sharply over the past year but details…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

AstraZeneca’s share price is down 20% from September, so is it time for me to buy?

AstraZeneca’s share price has fallen a long way this year, which could mean a bargain to be had, so I…

Read more »

Man smiling and working on laptop
Investing Articles

2 top gold ETFs to consider in May!

Buying a gold exchange traded fund this month is a great idea to consider as the precious metal targets new…

Read more »

Middle aged businesswoman using laptop while working from home
Investing Articles

3 dirt cheap FTSE 250 shares for May

I think these FTSE 250 shares could be among the London stock market's best bargains to consider following recent turbulence.

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

£500 to invest in an ISA each month? Here’s how to target a potential £60k+ second income!

A regular monthly investment in a Stocks and Shares ISA could build a huge passive income in retirement. Let me…

Read more »

Departure & Arrival sign, representing selling and buying in a portfolio
Investing Articles

£10,000 invested in Jet2 shares 1 year ago is now worth…

Jet2 shares jumped on Tuesday 29 April after a positive trading report boosted investor sentiment. Dr James Fox explores his…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

£10,000 invested in BT shares 5 years ago is now worth…

BT shares have shone over the past 12 months, and that’s a little painful for me to say, having touted…

Read more »

Businessman hand stacking up arrow on wooden block cubes
Investing Articles

I think this could be the best investment opportunity on the FTSE 100

Like many FTSE 100 stocks, this one has been through the mill in 2025. However, it hasn’t recovered, potentially offering…

Read more »